We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




Kininogen-1 Protein Linked to Early Cognitive Impairment in Parkinson’s

By LabMedica International staff writers
Posted on 03 Dec 2020
Cognitive impairment is a common feature in Parkinson's disease (PD), associated with increased morbidity and mortality. More...
An ongoing area of PD studies is the search for biomarkers that can provide prognostic information about cognitive impairment and other symptoms.

Cognitive impairment is a common non-motor symptom of Parkinson’s disease. Two distinct subtypes of cognitive dysfunction have been suggested in PD, including frontal executive dysfunction associated with dopaminergic loss, and the posterior/temporal subtype that affects visuospatial and semantic fluency function and correlates with cholinergic loss.

Clinical Neuroscientists at the Karolinska Institutet (Stockholm, Sweden) and their colleagues recruited 405 persons in the PD cohort of the AETIONOMY project in six university hospitals in France, Germany, and Sweden, between September 2015 and December 2017, including 251 patients with idiopathic PD, 25 with familial PD, 39 persons at risk for PD, and 90 healthy controls. Seventy-four Idiopathic PD patients with available cerebrospinal fluid (CSF) were included in the analyses.

A suspension bead array procedure was performed, utilizing polyclonal rabbit antibodies generated within the Human Protein Atlas project targeting 216 proteins. Proteins were selected either based on potential association to PD according to literature or by the teams’s previous neuroproteomic efforts. As a validation procedure, levels of kininogen in CSF were measured using a commercial enzyme‐linked immunosorbent assay (ELISA) kit (Abcam, Cambridge, UK). Dilution ratio was 1:100 and absorbance was measured by a Tecan Spark 10‐M plate reader (Tecan Group Ltd., Männedorf, Switzerland).

The team reported that in initial statistical analyses, they identified three proteins that were present at significantly higher levels in the CSF of those with low scores: kininogen-1 (KNG1), a disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), and kallikrein‐6 (KLK6). In subsequent analyses, which made statistical adjustments for possible confounding factors, KNG1 was significantly predictive of the Repeatable Battery for the Assessment of the Neuropsychological Status (RBANS score); that is, individuals with high KNG1 levels in their CSF were statistically more likely to have low RBANS scores. The other two proteins were not significantly associated with the RBANS score in these models.

The authors concluded that the results of a high‐throughput antibody‐based proteomic approach for the analysis of CSF markers related to early signs of cognitive impairment in PD and found that KNG1 levels in CSF were altered in PD patients with RBANS total score of low average level or less. The study was published in the November, 2020 issue of the journal Movement Disorders.

Related Links:
Karolinska Institutet
Abcam
Tecan Group Ltd



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.